98%
921
2 minutes
20
Background And Aims: Alagille syndrome (ALGS) is a multisystem disorder that maybe confused with biliary atresia (BA) shortly after birth. This study aimed to identify criteria for early distinction between these two diseases.
Methods: Patients with confirmed ALGS and BA were retrospectively enrolled in this study. Clinical data, biochemical results, ultrasound findings, liver histopathology, and genetic testing were analyzed.
Results: A total of 14 patients with ALGS under 3 months of age were included in this study, and compared with 28 age- and sex-matched patients with BA. (1) Clinical features: Significant differences in cardiac structural abnormalities and distinctive facial features were observed. (2) Biochemical indicators: Both groups showed elevated gamma-glutamyl transferase (GGT) levels. The GGT level in the ALGS group was 12.19-fold of the upper limit of normal (ULN), which was lower than that in the BA group (20.60-fold of ULN, P = 0.011). (3) Ultrasonography: ALGS patients had a lower gallbladder abnormality rate (64.3%, 9/14) than BA patients (96.4%, 27/28) (P < 0.05), and the incidence of hepatomegaly and splenomegaly in ALGS patients was significantly lower than that in BA (P < 0.05). (4) Liver histopathology: ALGS patients exhibited a significantly lower prevalence of bile duct proliferation (22.2% vs. 96.4%) and bile plugs (44.4% vs. 92.9%) compared to BA patients (P < 0.05). Additionally, fibrosis or cirrhosis was markedly less common in ALGS patients (11.1% vs. 60.7%, P = 0.019).
Conclusion: To effectively distinguish between ALGS and BA in infants under three months of age, clinicians should evaluate cardiac anomalies, distinctive facial features, serum GGT levels, ultrasound findings, and liver histopathology. In diagnostically challenging cases, intraoperative biliary exploration remains essential for timely diagnosis of BA. Genetic testing for JAG1 and NOTCH2 may aid in confirming ALGS when clinical and histological findings are inconclusive.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239444 | PMC |
http://dx.doi.org/10.1186/s12887-025-05896-y | DOI Listing |
J Clin Exp Hepatol
July 2025
Department of Pediatric Gastroenterology, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, India.
Cureus
July 2025
Department of Pediatrics, University Hospital Bonn, Bonn, DEU.
Alagille syndrome (ALGS) is a rare, autosomal dominant disorder characterized by cholestasis and progressive liver disease that can lead to liver transplantation or death. Liver transplant recipients with ALGS can face chronic graft dysfunction and refractory pruritus that significantly impairs quality of life. We present the case of a 16-year-old male patient with ALGS who developed severe pruritus 13 years after receiving a liver transplant.
View Article and Find Full Text PDFTransplant Proc
August 2025
Florya VM Medical Park Application and Research Hospital, Organ Transplantation Center, Dr. Istanbul Aydın University, Istanbul, Turkey.
Objective: Liver transplantation is currently the most treatment for fulminant hepatitis, end-stage liver failure, hepatocellular carcinoma, and liver-originated metabolic diseases in children. With technological advances, improvements in surgical techniques and immunosuppressive therapy protocols have increased 1-year survival rates to 80%-90%. Our center successfully performs both living donor and cadaveric liver transplants in children.
View Article and Find Full Text PDFIndian J Dermatol Venereol Leprol
August 2025
Department of Dermatology, Dr. B. R. Ambedkar Medical College and Hospital, Bengaluru, Karnataka, India.
Curr Opin Pediatr
October 2025
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Hassenfeld Children's Hospital, New York University Grossman School of Medicine, New York, New York, USA.
Purpose Of Review: To provide an update of recent advancements in pediatric hepatology, highlighting new diagnostic criteria, emerging therapeutic options, and molecular insights into liver diseases which are reshaping clinical practice and guiding future research.
Recent Findings: Nonalcoholic fatty liver disease (NAFLD) has been redefned as metabolic dysfunction-associated steatotic liver disease (MASLD), reflecting an improved understanding of its underlying pathophysiology. Advances in immunophenotyping have identified activated T-cell hepatitis as a significant contributor to indeterminate pediatric acute liver failure.